Patently Innovative: How Pharmaceutical Firms Use Emerging Patent Law to Extend Monopolies on Blockbuster Drugs

Patently innovative provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regulated and how government regulation can either stimulate or inhibit development of breakthrough products.

Dedication Acknowledgements List of figures and tables List of abbreviations About the author Chapter 1: Introduction Abstract: 1.1 The emergence of global pharmaceutical linkage 1.2 Canadian pharmaceutical linkage regulations 1.3 Organization Chapter 2: Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy Abstract: 2.1 Drug approval 2.2 Patents 2.3 Linkage regulations 2.4 IPR rights and innovation policy Chapter 3: Empirical analysis of drug approval Abstract: 3.1 Introduction 3.2 Analysis 3.3 Results 3.4 Discussion 3.5 Interpretation of data 3.6 Study limitations 3.7 Assessing the lifecycle approach: the long view 3.8 Government as representative public agent 3.9 Summary and conclusions Chapter 4: Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage Abstract: 4.1 Introduction 4.2 Methods 4.3 Results 4.4 Discussion Chapter 5: Empirical analysis of drug patenting in multiple high-value cohorts Abstract: 5.1 Introduction 5.2 Methods 5.3 Results 5.4 Discussion 5.5 Summary and conclusions Chapter 6: Implications of empirical data: are pharmaceutical linkage regulations a success? Abstract: 6.1 Introduction 6.2 Debate preceding Bill C-91 6.3 `Original policy intent' 6.4 `Patent-specific' analysis 6.5 Statutory interpretation 6.6 Revisiting the empirical data 6.7 Summary and conclusions Chapter 7: Future directions: testable hypotheses and evolution toward global pharmaceutical linkage Abstract: 7.1 Hypotheses regarding cluster-based drug development 7.2 Globalization of pharmaceutical linkage Index